Integra LifeSciences
IART
147 hedge funds and large institutions have $1.24B invested in Integra LifeSciences in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 60 increasing their positions, 44 reducing their positions, and 11 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 44
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
12% more call options, than puts
Call options by funds: $772K | Put options by funds: $691K
5% more capital invested
Capital invested by funds: $1.18B → $1.24B (+$61M)
2% more funds holding
Funds holding: 144 → 147 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$18.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$9.18M |
| 3 |
DM
Deerfield Management
New York
|
+$7.45M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$4.58M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boston Partners
Boston,
Massachusetts
|
-$19.1M |
| 2 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$5.93M |
| 3 |
EIP
Epoch Investment Partners
New York
|
-$2.82M |
| 4 |
NG
NatWest Group
Edinburgh, Scotland,
United Kingdom
|
-$2.59M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$1.91M |
IART Hedge Fund Activity: Q2 2014 in Review
147 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q2 2014, worth a combined $1.24B — up 5.2% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IART positions and 11 closed out — a net gain of 3 holders — while 60 added to existing stakes and 44 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $18.1M. The largest seller was Boston Partners, cutting an estimated $19.1M.
- 147 institutional investors held Integra LifeSciences (IART) as of Q2 2014, up from 144 in Q1 2014.
- Funds reported $1.24B of Integra LifeSciences stock for Q2 2014, up 5.2% quarter-over-quarter.
- 14 funds opened new Integra LifeSciences positions in Q2 2014 and 11 closed out, a net change of +3 holders.
- The largest Integra LifeSciences buyer in Q2 2014 was Goldman Sachs, an estimated $18.1M added.
- The largest Integra LifeSciences seller in Q2 2014 was Boston Partners, an estimated $19.1M sold.
Based on aggregated 13F filings for Q2 2014.